Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ:AVIR
Want to see AVIR full AI Analyst Report?
AVIR Stock Chart & Stats
$5.74
$0.04(1.19%)
At close: 4:00 PM EST
$5.74
$0.04(1.19%)
Day’s Range― - ―
52-Week Range$2.78 - $6.45
Previous CloseN/A
Volume180.19K
Average Volume (3M)324.34K
Market Cap
$378.53M
Enterprise Value$295.04M
Total Cash (Recent Filing)$256.01M
Total Debt (Recent Filing)$634.00K
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Aug 06, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.11
Shares Outstanding80,027,100
10 Day Avg. Volume368,036
30 Day Avg. Volume324,338
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)1.06
Price to Sales (P/S)0.00
P/FCF Ratio-2.20
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-116.94
Enterprise Value/Ebitda-1.59
Forecast
1Y Price Target
$7.05Price Target Upside22.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.93
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase‑3 Momentum And Trial DesignNear‑term, well‑powered Phase‑3 programs reduce binary development risk and increase the likelihood of regulatory submissions. Completed/near‑complete enrollment and clear primary endpoints support predictable timelines and a credible path to approval and commercialization over the next 6–18 months.
Regimen Potential — Efficacy And Low DDIA short, potent oral regimen with minimal DDIs and no food effect supports differentiated clinical utility and easier uptake by prescribers. Structurally, this enhances competitiveness versus existing DAAs and could simplify labeling, adherence, and payer discussions long term.
Balance Sheet Strength And Low LeverageExtremely low financial leverage provides flexibility to fund development and negotiate partnerships without immediate debt pressure. Combined with meaningful near‑term cash, this reduces short‑term insolvency risk and supports continued R&D execution and strategic options over the next 2–3 years.
Bears Say
Zero Revenue And Persistent LossesNo commercial revenue means operations depend on financing or partnerships; persistent high net losses and negative free cash flow increase dilution risk and constrain reinvestment capacity. Over months, this elevates execution risk if clinical milestones slip or funding terms worsen.
Runway Limited Beyond 2027Available cash appears sufficient to complete 2026 milestones but is unlikely to fund commercialization or extended development without extra capital. This structural financing need can force dilutive raises, asset sales, or partnerships that meaningfully affect long‑term ownership and strategy.
Regulatory Complexity Across RegionsDiffering primary analysis populations raise the risk of divergent regulatory interpretations, potential requests for additional analyses, and staggered approvals. Structurally this can delay global launch sequencing, complicate labeling, and increase cost and time to full market access.
Atea Pharmaceuticals News
AVIR FAQ
What was Atea Pharmaceuticals, Inc.’s price range in the past 12 months?
Atea Pharmaceuticals, Inc. lowest stock price was $2.78 and its highest was $6.45 in the past 12 months.
What is Atea Pharmaceuticals, Inc.’s market cap?
Atea Pharmaceuticals, Inc.’s market cap is $378.53M.
When is Atea Pharmaceuticals, Inc.’s upcoming earnings report date?
Atea Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 67 days.
How were Atea Pharmaceuticals, Inc.’s earnings last quarter?
Atea Pharmaceuticals, Inc. released its earnings results on May 12, 2026. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.555 by -$0.015.
Is Atea Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Atea Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Atea Pharmaceuticals, Inc. pay dividends?
Atea Pharmaceuticals, Inc. does not currently pay dividends.
What is Atea Pharmaceuticals, Inc.’s EPS estimate?
Atea Pharmaceuticals, Inc.’s EPS estimate is -0.56.
How many shares outstanding does Atea Pharmaceuticals, Inc. have?
Atea Pharmaceuticals, Inc. has 80,027,100 shares outstanding.
What happened to Atea Pharmaceuticals, Inc.’s price movement after its last earnings report?
Atea Pharmaceuticals, Inc. reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.555. Following the earnings report the stock price went down -16.909%.
Which hedge fund is a major shareholder of Atea Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in AVIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atea Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.05 (22.82% Upside)
$7.05 (22.82% Upside)
Blogger Sentiment
Bullish
AVIR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 12.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $25.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 11.3%
Last 30 Days ▼ 11.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
58.30%
12-Months-Change
Fundamentals
Return on Equity
-57.01%
Trailing 12-Months
Asset Growth
-39.30%
Trailing 12-Months
Company Description
Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
AVIR Company Deck
AVIR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a largely positive outlook driven by strong operational progress: completed enrollment for the U.S. Phase 3 (C‑BEYOND), near‑complete enrollment ex‑U.S. (C‑FORWARD), a well‑powered trial design (90% power, 5% non‑inferiority), an advancing HEV program (CTA enabling studies done, FIH mid‑year), clear prescriber interest, manufacturing readiness, and $256M in cash with runway through 2027. Key risks include a limited cash runway beyond 2027, higher R&D spend, regulatory complexity (different primary analysis populations for FDA vs EMA), payer and market access uncertainties, and clinical/regulatory risk for the novel HEV program. On balance, operational milestones and program momentum outweigh the noted risks.View all AVIR earnings summariesAVIR Stock 12 Month Forecast
Average Price Target
$7.05
▲(22.82% Upside)
Technical Analysis
Ownership Overview
11.07% Insiders
16.68% Mutual Funds
22.48% Other Institutional Investors
38.91% Public Companies and
Individual Investors